Roivant Sciences($ROIV)CEO Matt Gline 在 STAT Summit 对话中批评投资者对生物科技公司进行“degrossing”,称其违背了与药企的约定并伤害行业。他表示药企承担研发风险、产出数据并推动获批上市,投资者本应让价格反映业务现实,并呼吁投资者“把事情搞清楚”,认为当前市场噪音损害行业。
The "degrossing" situation came up during my #STATSummit conversation y'day with $ROIV CEO Matt Gline @gline. He was not amused / frustrated. Investors, he said, are violated their compact with biotech companies.
“We develop drugs, we take all kinds of risks, we generate data, and hopefully those data are positive. Then we get the drug approved and we launch it. In exchange, investors have one job, which is to make prices reflect the reality of what businesses do,” he told me.
“My message to investors is, get your shit together, guys. Get in a room and figure this out. This is nonsense. It’s noise, and it hurts our industry.”
https://www.statnews.com/2026/10/15/wall-street-biotech-trouble-stirring/
来源:Adam Feuerstein ✡️ · x.com